Overview on recent developments: alternative isotope production methods in Canada

The purpose of this paper is to provide an update on the Government of Canada's programs in alternative isotope production methods for securing supply of technetium 99m for Canadians. The supply disruptions of isotopes in 2007 and 2009/2010 caused by unplanned outages at AECL's National Research Universal (NRU) reactor highlighted the fragility of the supply chain that delivers medical isotopes, specifically Technetium 99m (Tc99m) to patients in Canada and globally. Tc99m, which is derived from its parent, molybdenum99 (Mo99) is the most widely used medical isotope for imaging, and accounts for 80 percent of nuclear medicine diagnostic procedures. Prior to the outage, nearly all the Mo99 produced for the world market came from five aging government owned research reactors in Canada, France, the Netherlands, Belgium and South Africa. The NRU, the largest of these, produced about 30 to 40 percent of the world supply of isotopes prior to 2009 - since its return to service in 2010, its world market share is estimated at 15 to 20%.